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Results: HIV prevalence was 17.0% (95% Confidence Interval: 15.7
18.3%) among men and 30.1% (28.531.6%) among women. Overall,
59.1% (57.460.8%) of men and 79.5% (78.280.9%) of women
reported having ever been tested for HIV. When controlling for age,
circumcised men were more likely to ever have been tested (66.1%
vs. 53.6%; pB0.001). Among HIV individuals, 21.0% (17.724.6%)
of men and 30.5% (27.733.3%) of women tested positive for any
ARV. The ratio of ARV people over those HIV was 0.084. Using
basic calculations, we found that if ART programs were actually
treating all eligible patients since 2005, this ratio should have been
0.210.28, indicating an effectiveness of ART programs around
4763%. Among ARV participants, 91.9% (88.794.3%) had viral
suppression (VLB400 cp/mL). The proportion of viral suppression
among HIV was 27.0% (24.329.9%) among women and 17.5%
(14.420.9%) among men. These proportions were lower among the
highly-exposed age groups: 15.6% (12.119.7%) among women and
8.4% (5.013.1%) among men.
Conclusions: In Orange Farm, in the 20052012 period, ART pro-
grams were sub-optimal and, among HIV, proportion of viral
suppression was low, especially among the highly-exposed age
groups. This suggests that, up to 2012, ART programs may not have
substantially impacted HIV incidence. However, our study showed at
community level that, when effectively taken, ARVs present a high
effectiveness in suppressing VL.
http://dx.doi.org/10.7448/IAS.18.5.20338
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Introduction: Panama adopted Treatment as Prevention (TasP) in
February 2014 and is now seeking efficient and effective ways to
expand antiretroviral therapy (ART) coverage in key populations. We
developed a mathematical model to determine the ART coverage
and associated costs required to meet HIV incidence reduction
targets for the female sex worker (FSW) population, which has a
1.6% HIV prevalence.
Methods: The Government of Panama, British Columbia Centre for
Excellence in HIV/AIDS and Simon Fraser University are collaborat-
ing to develop mathematical models for informing Panama’s TasP
strategy. Quantitative and qualitative information was collected from
national reports, key informant interviews and focus groups with
civil society to inform a compartmental HIV transmission model
incorporating disease progression and treatment. The model was
calibrated and validated for 2013. Estimated FSW population size is
17,000 and according to the Global AIDS Response Progress report,
current ART coverage for both FSW and the hard-to-reach client
population is about 47%. Annual ART cost/individual is US$625.
Simulation scenarios for meeting 50, 70 or 90% reduction in HIV
incidence in FSW in 15 years assumed ART expansion either for FSW
and their clients (Scenario 1) or for FSW only (Scenario 2).
Results: ART expansion for FSW costs slightly more in Scenario 1 than
2. However, overall for both populations of FSW and clients, more
infections are averted and treatment programme costs are lower
for the strategy targeting FSW only (see Table 1). Furthermore, initial
aggressive expansion of ART coverage leads to overall cost savings
and a more effective means of averting new infections (see Figure 1).
The result of no action compared to the 90% Scenario 2 strategy
would be 170% more HIV infections and 50% more treatment costs
over 15 years.
Conclusions: Rapid expansion of TasP for female sex workers in
Panama would avert infections and treatment costs already within
15 years. Initial short-term investment to increase ART coverage
would be offset by long-term savings. Since Panama adopted TasP,
UNAIDS has announced the 909090 targets for HIV diagnosis,
treatment and suppression, which call for an even more rapid
reduction in incidence. Ongoing analyses are evaluating costs and
outcomes of reaching the new targets by 2020.
http://dx.doi.org/10.7448/IAS.18.5.20339
MOAC0104
Does a universal test and treat strategy impact ART
adherence in rural South Africa? ANRS 12249 TasP
cluster-randomized trial
Collins Iwuji1,2; Rosemary Dray-Spira3; Alexandra Calmy4;
Joseph Larmarange1,5; Joanna Orne-Gliemann6; Franc¸ois Dabis6;
Deenan Pillay1,7 and Kholoud Porter8
Abstract MOAC0103Table 1. Outcomes and costs of TasP expansion scenarios
Population
Target incidence
reduction in FSW
in 15 years (%)
No ART
expansion new
cases in 15 years
No ARTexpansion
US$ costs in 15
years
TasP Scenario 1
new cases in 15
years
TasP Scenario
1 US$ costs in
15 years
TasP Scenario 2
new cases in 15
years
TasP Scenario 2
US$ costs in 15
years
FSW 50 2816 $1,240,560 2003 $911,016 2000 $1,025,737
Clients 50 4096 $3,841,072 2878 $3,308,139 2847 $3,139,332
Both 50 6912 $5,061,632 4881 $4,219,155 4847 $4,165,069
FSW 70 2816 $1,240,560 1620 $863,324 1605 $1,093,578
Clients 70 4096 $3,841,072 2331 $3,030,029 2259 $2,782,224
Both 70 6912 $5,061,632 3951 $3,893,353 3864 $3,875,802
FSW 90 2816 $1,240,560 1118 $777,438 1074 $1,107,593
Clients 90 4096 $3,841,072 1615 $2,818,353 1480 $2,260,854
Both 90 6912 $5,061,632 2733 $3,595,791 2554 $3,368,447
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Introduction: HIV treatment guidelines are recommending ART at
increasingly higher CD4 counts for maximizing individual and
population benefits. However, the expansion of ART use may be at
the expense of optimal adherence. We report on adherence and
virological suppression when initiating ART at different CD4 thresh-
olds within the Treatment as Prevention (ANRS 12249) trial of
universal home-based testing and immediate ART initiation in rural
KwaZulu-Natal.
Methods: Using data of a cluster-randomized trial of immediate
ART versus initiation according to current national guidelines
(CD45350 cells/mm3), we compared adherence levels (]95% vs.
B95%) measured using a visual analogue scale (VAS) and pill
count (PC) and virological suppression at six months (B400 c/mL)
according to CD4 count at ART initiation through logistic regression
models, adjusting for possible confounders (age, sex, marital status,
education and employment).
Results: During March 2012May 2014, 601 participants who were
not on ART entered care in trial clinics; 382 initiated ART; 254 have
completed ]6 months on ART, 227 of whom had six months HIV RNA
data and were included in analyses. One hundred sixty-nine were
women; median (IQR) age and CD4 at ART initiation were 35 years
(28, 46) and 313 cells/mm3 (206, 513). Adherence ]95% at six
months was high (88 and 83% by PC and VAS, respectively) with no
evidence that this was associated with CD4 at initiation (aOR0.97
per 100 cells/mm3 higher, 95% CI: 0.831.12, p0.65 for VAS; aOR
1.13 per 100 cells/mm3 higher, 0.981.31, p0.09 for PC). Male sex
was independently associated with B95% adherence (2.58, 1.24
5.35, p0.01; ref. females). Eighty-three percent (183/227) of those
who started ART achieved HIV suppression by six months with no
association with CD4 at initiation (1.13 per 100 cells/mm3 higher,
0.961.33, p0.40). Compared to those with ]95% adherence by
VAS, individuals with B95% adherence were somewhat less likely to
suppress (0.44, 0.191.03, p0.06).
Conclusions: We found no evidence that, among people newly
entering HIV care, higher CD4 at ART initiation was associated with
reduced adherence or poorer virological suppression, at least in the
short-term. In this rural South African setting, motivation to adhere
to ART may be independent of the presence of symptomatic HIV
disease.
http://dx.doi.org/10.7448/IAS.18.5.20340
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Introduction: To have a population impact in generalized HIV
epidemics in Africa, high coverage of combination HIV preven-
tion strategies that reduce the susceptibility of uninfected persons
and the infectiousness of infected persons is needed. Community-
based HIV testing and counselling, with linkage to care and
prevention, is a potential delivery platform for combination HIV
prevention.
Methods: We conducted a multisite programme of community-based
HIV testing and counselling, linkage to HIV care, and demand creation
for voluntary medical male circumcision (VMMC) in rural commu-
nities in KwaZulu-Natal, South Africa and Sheema district, Uganda.
HIV testing was done at home or through mobile units. HIV-positive
persons were randomly allocated to linkage to care strategies: clinic
facilitation by lay-counsellors at the initial clinic visit, lay-counsellor
follow-up visits at home, or standard clinic referral. HIV-negative
uncircumcised men were randomized to VMMC demand creation
strategies: lay counsellor follow-up visits at home, SMS reminders, or
standard VMMC promotion at the time of testing.
Results: Between June 2013 and February 2015, 15,332 persons
received HIV testing and counselling. Among 1325 HIV-positive
persons randomized to linkage strategies, the overall clinic linkage
was high (93%). Compared to standard linkage, lay counsellor clinic
facilitation increased linkage to care (RR1.09, 95% CI: 1.051.13),
and home follow-up visits increased antiretroviral therapy (ART)
initiation (RR1.23, 95% CI: 1.021.47). In all arms, ART initiation
was limited by bottlenecks in service delivery at the clinics, although
67% of those eligible initiated ART by nine months. Overall, 82% of
persons initiating ART achieved viral suppression without significant
difference between study arms. Of 750 HIV-negative uncircumcised
men randomized to VMMC promotion strategies, the uptake of
circumcision was 41% by month 3. Compared to standard messages,
VMMC uptake was significantly higher in the SMS promotion
(RR1.72, 95% CI: 1.362.17) and lay counsellor follow-up arms
(and RR1.67, 95% CI: 1.292.14).
Conclusions: Community-based HIV testing and linkage to care and
prevention effectively deliver combination HIV prevention. Simple
strategies, such as SMS reminders or lay-counsellor visits, increase
linkage for ART initiation and male circumcision. Community-based
strategies require integration with efficient clinical services, and
Abstract MOAC0103Figure 1. Treatment cost for FSW population.
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